Percutaneous transluminal angioplasty (PTA) is a minimally invasive endovascular procedure that can open up a blocked blood vessel using a catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored. PTA balloons come in various shapes, lengths, and sizes, depending on the anatomy they are intended to treat. PTA balloon catheters are used to treat peripheral vascular lesions and vascular blockages. The PTA balloon catheter market growth can be attributed to the increasing prevalence of urological and cardiovascular diseases worldwide.
According to the World Health Organization (WHO), cardiovascular diseases (CVDs) are the leading cause of death worldwide, taking an estimated 17.9 million lives each year. Moreover, according to the Centers for Disease Control and Prevention (CDC), around 655,000 people in the United States die from heart disease each year, that is 1 in every 4 deaths. Thus, with the increasing prevalence of urological and cardiovascular diseases, the demand for PTA balloon catheters is also increasing with a rapid pace. This in turn is expected to augment the growth of the PTA balloon catheter market growth. In March 2021, Medtronic launched PTA balloon catheter in the following countries: Turkey, Spain, South Africa, Portugal, Italy, and Germany.
The device is indicated for use in native or synthetic arteriovenous dialysis fistulae, as well as femoral, iliac, and renal arteries. The device enables the infusion of diagnostic or therapeutic fluids via the integrated injection port located proximal to the balloon. Moreover, an increasing number of minimally invasive surgeries and the growing geriatric population are some major factors driving the PTA balloon catheter market growth. Minimally invasive procedures have led to an increase in the number of catheterization laboratories. According to the WHO, world's population aged 60 years and older is expected to total 2 billion by 2050.
Moreover, the booming medical tourism industry is expected to have a positive impact on the PTA balloon catheter market. Market player are focused on launching new and innovative balloon catheters to meet the increasing demand, especially in North America and the Asia Pacific. For instance, in January 2021, OrbusNeich Medical Co. Ltd. received the United States Food and Drug Administration (USFDA) approval for the JADE 0.014”, 0.018” and 0.035” OTW non-compliant peripheral balloon dilatation catheter series. The JADE is a PTA OTW balloon catheter for Percutaneous Transluminal Angioplasty in the peripheral vasculature.
No comments:
Post a Comment